Pharmacogenomics to Predict Responses to SGLT2 Inhibitors

Trial Profile

Pharmacogenomics to Predict Responses to SGLT2 Inhibitors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 23 Apr 2018 Planned number of patients changed from 650 to 700.
    • 23 Apr 2018 Planned End Date changed from 1 Jul 2021 to 30 Jun 2023.
    • 23 Apr 2018 Planned primary completion date changed from 1 Jul 2021 to 30 Jun 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top